FDA, Pharma, and the Approval Dilemma

This chapter examines the troubling relationship between the FDA and the pharmaceutical industry, particularly in the context of Biogen's Alzheimer's drug approval process. It raises critical questions about bias, advocacy influence, and the need for reform in drug development to prioritize public health over profit.